{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T21:04:55Z","timestamp":1771535095472,"version":"3.50.1"},"reference-count":18,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"published-print":{"date-parts":[[2022]]},"abstract":"<b><i>Introduction:<\/i><\/b> The clinical implications of plasma Epstein-Barr virus (EBV) DNA in patients with peripheral T-cell lymphoma (PTCL) remain unclear. <b><i>Objective:<\/i><\/b> This study aimed to explore the clinical correlations of pre- and post-treatment plasma EBV-DNA concentrations with treatment outcomes and prognosis in patients with PTCL. <b><i>Methods:<\/i><\/b> We retrospectively reviewed 128 patients diagnosed with PTCL with available data on pre-treatment plasma EBV-DNA, including 63 patients for whom post-treatment plasma EBV-DNA data were also available. Patients with extra-nodal NK\/T-<X00_Del_TrennDivis><\/X00_Del_TrennDivis>cell lymphoma were excluded from this study. <b><i>Results:<\/i><\/b> Pre-treatment plasma EBV-DNA was elevated (e.g., \u2265500 copies\/mL) in 35.2% of PTCL patients, with significant differences in positive rates between different subtypes of PTCL (<i>p<\/i> &#x3c; 0.001). High pre-treatment EBV-DNA concentrations were associated with advanced age (&#x3e;60 years), elevated lactate dehydrogenase levels, high International Prognostic Index (IPI), and positive EBV-encoded RNAs-ISH in tumor specimens. In multivariate analyses, pre-treatment EBV-DNA \u2265500 copies\/mL was an independent prognostic factor after adjusting for IPI and pathological subtypes (hazard ratio = 2.14, <i>p<\/i> = 0.032). For patients with elevated pre-treatment EBV-DNA, normalization of EBV-DNA concentrations after first-line chemotherapy was significantly associated with better overall response rate (81.3% vs. 22.2%, <i>p<\/i> = 0.014), progression-free survival (12.0 months vs. 3.7 months, <i>p<\/i> = 0.011), and overall survival (37.9 months vs. 7.8 months, <i>p<\/i> = 0.012). For patients achieving remission to first-line therapy, rebound of EBV-DNA levels during follow-up was associated with disease relapse or progression. <b><i>Conclusions:<\/i><\/b> These results suggest that pre-treatment plasma EBV-DNA concentration is a strong prognostic factor for PTCL. For patients with elevated pre-treatment EBV-DNA, dynamic monitoring of EBV-DNA changes after initiation of therapy is useful for predicting treatment outcome and disease relapse. <\/jats:p>","DOI":"10.1159\/000516588","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T22:00:41Z","timestamp":1636495241000},"page":"132-143","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Significance of Plasma Epstein-Barr Virus DNA in Peripheral T-Cell Lymphomas"],"prefix":"10.1159","volume":"145","author":[{"given":"Danqing","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoxuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2014.12.030"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-017632"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30566"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21251"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2007.05.020"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-435024"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-454694"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2007.08.013"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1300894"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4505"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032260"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-672030"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23858"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2003.10.013"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199501000-00006"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1563690"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/516588","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/516588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T14:57:01Z","timestamp":1745420221000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000516588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,23]]},"published-print":{"date-parts":[[2022,4,19]]}},"URL":"https:\/\/doi.org\/10.1159\/000516588","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.16960816","asserted-by":"subject"}]},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,9]]}}}